As biology becomes programmable and AI accelerates discovery, startups are generating breakthrough innovations at unprecedented speed. Yet translating these advances into real-world therapies still depends on effective collaboration with global pharmaceutical organizations. This session explores how the innovation ecosystem connects early-stage breakthroughs to scalable development, bringing together leaders from startup incubation, external innovation, and pharma strategy. Speakers will examine how AI-native biotech companies engage with pharma today: how startups become “pharma-ready,” how external innovation teams evaluate and structure partnerships, and what collaboration models are emerging as biology and computation converge. From early ecosystem support and venture building to strategic alliances and co-development pathways, the discussion will provide a practical look at how ideas move from discovery to patient impact in the AI era.